A NOVEL STRATEGY USING G-CSF TO SUPPORT EMA CO FOR HIGH-RISK GESTATIONAL TROPHOBLASTIC DISEASE

Citation
Em. Hartenbach et al., A NOVEL STRATEGY USING G-CSF TO SUPPORT EMA CO FOR HIGH-RISK GESTATIONAL TROPHOBLASTIC DISEASE, Gynecologic oncology, 56(1), 1995, pp. 105-108
Citations number
22
Categorie Soggetti
Oncology,"Obsetric & Gynecology
Journal title
ISSN journal
00908258
Volume
56
Issue
1
Year of publication
1995
Pages
105 - 108
Database
ISI
SICI code
0090-8258(1995)56:1<105:ANSUGT>2.0.ZU;2-Y
Abstract
EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is a n effective and well-tolerated chemotherapy regimen for the treatment of high-risk gestational trophoblastic disease. However, it is associa ted with significant neutropenia often requiring dose reductions and t reatment delays. We describe the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment s chedule. A subcutaneous injection of 5 mug/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adve rse effects and all received full chemotherapy doses without any treat ment delay. The addition of G-CSF to the EMA/CO regimen may benefit pa tients by achieving dose intensity in the treatment of high-risk gesta tional trophoblastic disease. (C) 1995 Academic Press, Inc.